Advisory committee reform for the US Food and Drug Administration’s Center for Drug Evaluation and Research includes product-specific adjustments to the group offering advice.
CDER Director Patrizia Cavazzoni expects more temporary members could be added to advisory committees going forward to ensure the groups’ “expertise applies precisely to the matters under consideration,” according to slides she
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?